PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2558131

Rapidly enlarging gingival mass.

J A Svirsky·C D Dent·D Mandalinich
View original source ↗Export metadata ↓

Abstract

A case of small cell carcinoma metastatic to the mandible has been detailed. The lesion involved both hard and soft tissues and it was impossible to determine the site to which it first spread. Because of the histological similarity to the primary lung lesion and evidence of metastatic spread to other body organs, this lesion was considered to be metastatic rather than a primary tumor. The importance of accurate diagnosis was discussed, and treatment options were presented.

Explore related subjects

Carcinoma, Small CellDiagnosis, DifferentialGingival NeoplasmsHumansLung NeoplasmsMaleMandibular NeoplasmsMiddle AgedCase ReportsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Svirsky, C D Dent, D Mandalinich. 1989. Rapidly enlarging gingival mass.. https://doi.org/10.1016/s0002-8177(89)95021-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

Carcinoma, Small Cell↗